Navigation Links
Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call
Date:4/23/2008

BOTHELL, Wash., April 23 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced today that it will release its first quarter 2008 financial results on Wednesday, April 30, 2008 after the market close. The Company has scheduled a conference call with analysts and investors for 4:30 p.m. Eastern Time to discuss the financial results for the first quarter and current business developments. The call will be hosted by John Hinson, president and chief executive officer, and Michael Matysik, senior vice president and chief financial officer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

To access the conference call, please dial 800-257-3401. International participants can dial 303-262-2125. The call will also be webcast live at http://www.cardiacscience.com. An audio replay of the call will be available for 7 days following the call at (800) 405-2236 for U.S. callers or (303) 590-3000 for those calling outside the U.S. The password required to access the replay is 11113278#. An archived webcast will also be available at http://www.cardiacscience.com for 90 days.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Company Contact:

Mike Matysik

Cardiac Science Corporation

Sr. Vice President and CFO

(425) 402-2009

Investor Contact:

Doug Sherk

Jenifer Kirtland

EVC Group, Inc.

(415) 896-6820

Media Contact:

Christopher Gale

EVC Group, Inc.

(201) 646-5431

(203) 570-4681

cgale@evcgroup.com CSCX-F


'/>"/>
SOURCE Cardiac Science Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
2. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
3. Australia Chooses Cardiac Science to Equip Its Defence Force
4. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
5. Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness
6. Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business
7. New research shows that iPods do not interfere with cardiac pacemakers
8. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
9. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
10. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
11. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):